Pill Identifier App

GSK and Shenzhen Neptunus Create New Alliance to Develop and Manufacture Influenza Vaccines in China

LONDON, June 9, 2009--GlaxoSmithKline plc (GSK) today announced it has entered into a definitive agreement to form a new Joint Venture with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd (Shenzhen Neptunus) focused on developing and manufacturing influenza vaccines for the Chinese market.

Jean Stéphenne, President and General Manager of GlaxoSmithKline Biologicals, said, “This new alliance enables GSK to build new vaccines capability in a critical emerging market such as China.  The new Joint Venture will combine the potential of GSK’s adjuvant technology and expertise in vaccine development together with the extensive experience of Shenzhen Neptunus in the Chinese vaccines market.  Together we will gain access to specific local influenza antigens and make available new vaccines to benefit public health in China and neighbouring territories.”

The alliance will develop and manufacture influenza vaccines for China, Hong Kong and Macau.  This will include vaccines for seasonal, pre-pandemic and pandemic influenza.  It is expected that these vaccines will become available over the next few years.  The Joint Venture is expected to benefit from the differing expertise that both companies have in developing vaccines.  Specifically, GSK will provide access to its proprietary adjuvant system which helps to improve efficiency and optimise production by increasing the number of vaccine doses that can be produced using a smaller amount of antigen.  Shenzhen Neptunus will provide additional local manufacturing capacity and R&D expertise.  Both companies will provide further investment in manufacturing.

GSK will take a 40% stake in the Joint Venture for a contribution of cash and assets equivalent to £21m.  Shenzhen Neptunus will take a 60% stake in the Joint Venture for a contribution of cash and assets equivalent to £31m.  Profits attributable to these assets are negligible.

Under the terms of the agreement, GSK is expected to purchase additional shares and obtain a majority equity interest in the Joint Venture within the next two years.

Completion of the transaction is expected in the fourth quarter of 2009, subject to local regulatory approval.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

Enquiries:

UK Media enquiries:
 Philip Thomson
 (020) 8047 5502
 
 
 David Outhwaite
 (020) 8047 5502
 
 
 Stephen Rea
 (020) 8047 5502
 
 
  
  
 
US Media enquiries:
 Nancy Pekarek
 (919) 483 2839
 
 
 Mary Anne Rhyne
 (919) 483 2839
 
 
 Kevin Colgan
 (919) 483 2839
 
 
 Lisa Behrens
 (919) 483 2839

European Analyst/Investor enquiries:
 David Mawdsley
 (020) 8047 5564

 Sally Ferguson
 (020) 8047 5543

 Gary Davies
 (020) 8047 5503

US Analyst/ Investor enquiries:
 Tom Curry
 (215) 751 5419

 Jen Hill Baxter
 (215) 751 7002

 

Posted: June 2009


View comments

Hide
(web2)